IDEAYA Biosciences (IDYA) FCF Margin (2020 - 2026)

IDEAYA Biosciences (IDYA) posted FCF Margin of 1160.62% for Q1 2026, down 36.86% sequentially from 848.06% in Q4 2025.

IDEAYA Biosciences (IDYA) FCF Margin (2020 - 2026) Analysis & Trends

IDEAYA Biosciences has reported FCF Margin for 7 years, with the latest figure at 1160.62% in Q1 2026.

Quarterly FCF Margin changed N/A year-over-year to 1160.62% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.15% (changed N/A YoY) and the FY2025 annual result came in at 33.59%, up 352445.0% from the prior year.
FCF Margin eased to 1160.62% in Q1 2026 per IDYA's latest filing, from 848.06% in the prior quarter.
Over five years, FCF Margin peaked at 69.08% in Q3 2025 and troughed at 1740.8% in Q4 2024.
A 5-year average of 593.26% and a median of 445.98% in 2022 frame the typical range for FCF Margin.
The sharpest annual moves came in 2024 and 2025: FCF Margin plunged 111393 bps in 2024, then jumped 89274 bps in 2025.
Over 5 years, FCF Margin stood at 505.0% in 2022, then retreated by 24 bps to 626.87% in 2023, then sank by 178 bps to 1740.8% in 2024, then surged by 51 bps to 848.06% in 2025, then tumbled by 37 bps to 1160.62% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 1160.62%, 848.06%, and 69.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	IDEAYA Biosciences	3.50 Bn	2.67 Bn	-	-1,003.08%

Download Data